Pharmaceuticals 5 August 2026

AbCellera Shares Jump 34% After ABCL635 Passes Phase 2 Trial

Shares of AbCellera Biologics Inc. jumped 34% on Monday following positive Phase 2 results for its investigational menopause treatment, which achieved both primary efficacy measures. The results position ABCL635 as the most significant asset in AbCellera’s internal pipeline.

11 August 2026

Biotechnology·NASDAQ:ABCL·Pharmaceuticals·Stock Market

Sionna Stock Falls 91% as Failed CF Trial Pushes Valuation Below Cash

Sionna Therapeutics closed 91.2% lower on Monday after its lead clinical readout failed. The company will not advance SION-719 as an add-on therapy in its current form.

11 August 2026

NASDAQ:SION·Pharmaceuticals·Stock Market

Bristol Myers Commits $2.3 Billion to Flexible Houston Drug Campus

Bristol Myers Squibb will spend about $2.3 billion on a modular drug-manufacturing campus in Houston. The 600,000-square-foot site will make small molecules, biologics and antibody-drug conjugates.

10 August 2026

NYSE:BMY·Pharmaceuticals·Stock Market

Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing

NEW YORK, Aug. 10, 2026, 4:06 p.m. EDT — Silence Therapeutics plc jumped over 25% in late trading on Monday as the company reported its investigational RNA-interference drug divesiran reached all primary and secondary endpoints in a randomized Phase 2 polycythemia vera trial. While overall efficacy was notable, investors appeared to focus on a less obvious outcome: the therapy showed sustained activity with dosing every 12 weeks.

10 August 2026

Biotechnology·NASDAQ:SLN·Pharmaceuticals·Stock Market

Eli Lilly (NYSE:LLY) gains $30 billion following UK approval for Foundayo; NHS access remains pending

Eli Lilly and Company’s Foundayo received approval in Britain for weight management and type 2 diabetes on Monday. Shares last traded at approximately $1,220, up 2.9%, as of 14:19 EDT, valuing the company near $1.09 trillion.

10 August 2026

NYSE:LLY·Pharmaceuticals·Stock Market

AbCellera (NASDAQ:ABCL) jumps 37.5% as hot-flash trial hits all main and secondary goals

Shares of AbCellera Biologics Inc. jumped 37.5% after the company announced its menopause therapy met both primary endpoints in a Phase 2 study. The stock was last trading at $9.53 at 13:58 EDT, having earlier reached a session high of $10.01.

10 August 2026

Biotechnology·NASDAQ:ABCL·Pharmaceuticals·Stock Market

Sionna Therapeutics (NASDAQ:SION) Drops 92% After Failed Study, Shares Fall Below Gross Cash

WALTHAM, Massachusetts, August 10, 2026, 12:00 EDT — Sionna Therapeutics fell 92% after its study missed its main goal, sending the stock below the company's reported gross cash position.

10 August 2026

Biotechnology·NASDAQ:SION·Pharmaceuticals·Stock Market

Tenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints

NEW YORK, Aug. 10, 2026 — Shares of Tenax Therapeutics tumbled around 85% ahead of Monday’s market open after the company reported that its Phase 3 LEVEL trial with oral levosimendan did not achieve its primary endpoint for exercise capacity or its main symptom endpoint.

10 August 2026

NASDAQ:TENX·Pharmaceuticals·Stock Market

Pfizer Shares Offer 6.4% Yield, Surpassing Wall Street Optimism After Results

Pfizer Inc. ended Friday’s session at $26.76, marking its sixth consecutive day of gains. Shares climbed 7.0% across the week, outpacing the S&P 500’s performance by almost double.

9 August 2026

Earnings·NYSE:PFE·Pharmaceuticals·Stock Market

Johnson & Johnson (NYSE:JNJ) Shares Steady at High Levels Even After 5.5% Earnings Revision

Johnson & Johnson closed Friday at $259.24, marking its highest finish since July 29. Shares remain 5.7% under the 52-week high of $274.90.

8 August 2026

Earnings·NYSE:JNJ·Pharmaceuticals·Stock Market

Pfizer (NYSE:PFE) climbs 7% after main drugs offset fall in COVID sales

The quarter delivered clear sales support for Pfizer's weekly upward trend. Four non-COVID segments generated an additional $797 million compared to the previous year. This amount was 1.5 times greater than the total decline seen in Comirnaty and Paxlovid.

8 August 2026

Earnings·NYSE:PFE·Pharmaceuticals·Stock Market

Zoetis Shares Approach 52-Week Low; Buybacks Support EPS Following Outlook Reduction

NEW YORK, August 8, 2026, 12:13 EDT – Zoetis stock slid close to its lowest level in 52 weeks after the company reduced its guidance, with share repurchases helping to stabilize earnings per share.

8 August 2026

Earnings·NYSE:ZTS·Pharmaceuticals·Stock Market

AbCellera (NASDAQ:ABCL) Shares Surge Ahead of Monday’s ABCL635 Phase 2 Trial Results

AbCellera Biologics Inc. advanced 9.7% in after-hours trade on Friday. The gain came after the company confirmed it will release ABCL635 Phase 2 results on Monday. Nasdaq will remain closed over the weekend.

8 August 2026

Biotechnology·NASDAQ:ABCL·Pharmaceuticals·Stock Market

Iovance shares surge 43% as Amtagvi revenue highlights manufacturing turning point

Iovance Biotherapeutics climbed 43.1% on Thursday following a record quarter for sales. The stock ended the session at $6.21, having peaked at $6.39, which marked a 52-week high. Ahead of Friday’s open, the shares last changed hands at $6.24.

7 August 2026

Biotechnology·NASDAQ:IOVA·Pharmaceuticals·Stock Market

Pfizer (NYSE:PFE) Shares Advance as COVID Pressures Offset by Core Improvement

Shares of Pfizer Inc. continued to climb following its earnings report on Thursday, trading around 4.0% higher compared to the closing level before results on Monday.

6 August 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Iovance shares surge 39% as Amtagvi Q2 revenue and margins surpass expectations

Iovance Biotherapeutics, Inc. climbed 39.2% early Thursday after the company posted record revenue for its second quarter. Shares changed hands at $6.04 as of 10:49 a.m. EDT, having previously reached a new 52-week peak of $6.385.

6 August 2026

Earnings·NASDAQ:IOVA·Pharmaceuticals·Stock Market

Geron (NASDAQ:GERN) rises as Rytelo sales move guidance midpoint within range

Shares of Geron rose on Wednesday, as Rytelo sales continued to climb for another quarter. At the current rate, second-quarter sales would annualize at $229.9 million, aligning closely with the midpoint of Geron's 2026 revenue forecast.

5 August 2026

Earnings·NASDAQ:GERN·Pharmaceuticals·Stock Market

Pfizer (NYSE:PFE) Shares Gain as Four Major Drugs Compensate for COVID Revenue Hit

NEW YORK, August 5, 2026, 09:11 EDT — Pfizer shares moved higher in U.S. premarket trade as four key therapies countered the drop in COVID-related revenue by 1.5 times.

5 August 2026

Earnings·NYSE:PFE·Pharmaceuticals·Stock Market

Eli Lilly Q2 growth focus: Mounjaro and Zepbound seen as drivers for up to 98% of quarterly increase

Eli Lilly and Company is set for a tight earnings test on Wednesday. Initial projections indicate that Mounjaro and Zepbound will account for about 98% of the revenue increase in the second quarter.

5 August 2026

Earnings·NYSE:LLY·Pharmaceuticals·Stock Market

Novo Nordisk shares (CPH:NOVO-B; NYSE:NVO) drop 4% after cost-driven profit outpaces forecasts but Wegovy concerns persist

COPENHAGEN, August 5, 2026, 10:26 CEST — Novo Nordisk saw its stock decline by 4% as the company's profit, which surpassed estimates due to reduced costs, did not fully address ongoing uncertainties over its Wegovy product.

5 August 2026

Earnings·NYSE:NVO·Pharmaceuticals·Stock Market

Pharmaceuticals 5 August 2026 - 11 August 2026

AbCellera Shares Jump 34% After ABCL635 Passes Phase 2 Trial

Sionna Stock Falls 91% as Failed CF Trial Pushes Valuation Below Cash

Bristol Myers Commits $2.3 Billion to Flexible Houston Drug Campus

Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing

Eli Lilly (NYSE:LLY) gains $30 billion following UK approval for Foundayo; NHS access remains pending

AbCellera (NASDAQ:ABCL) jumps 37.5% as hot-flash trial hits all main and secondary goals

Sionna Therapeutics (NASDAQ:SION) Drops 92% After Failed Study, Shares Fall Below Gross Cash

Tenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints

Pfizer Shares Offer 6.4% Yield, Surpassing Wall Street Optimism After Results

Johnson & Johnson (NYSE:JNJ) Shares Steady at High Levels Even After 5.5% Earnings Revision

Pfizer (NYSE:PFE) climbs 7% after main drugs offset fall in COVID sales

Zoetis Shares Approach 52-Week Low; Buybacks Support EPS Following Outlook Reduction

AbCellera (NASDAQ:ABCL) Shares Surge Ahead of Monday’s ABCL635 Phase 2 Trial Results

Iovance shares surge 43% as Amtagvi revenue highlights manufacturing turning point

Pfizer (NYSE:PFE) Shares Advance as COVID Pressures Offset by Core Improvement

Iovance shares surge 39% as Amtagvi Q2 revenue and margins surpass expectations

Geron (NASDAQ:GERN) rises as Rytelo sales move guidance midpoint within range

Pfizer (NYSE:PFE) Shares Gain as Four Major Drugs Compensate for COVID Revenue Hit

Eli Lilly Q2 growth focus: Mounjaro and Zepbound seen as drivers for up to 98% of quarterly increase

Novo Nordisk shares (CPH:NOVO-B; NYSE:NVO) drop 4% after cost-driven profit outpaces forecasts but Wegovy concerns persist

TechStock² Updates

Riot Platforms (RIOT) Rises as $9.1 Billion AI Deal Sets Higher Benchmark for Delivery

CAVA Shares Climb 12% Despite Margin Dip as Customer Traffic Rises

Cisco shares fall after earnings highlight $3.7 billion AI order surge

Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up

JetBlue Shares Bounce 3% After Four-Session Losing Streak; Volume Remains Light

Top Stock Picks

Taiwan Semiconductor

AerCap

Constellation Energy

Walt Disney

American International Group

Live updates

Investment Disclaimer